|

Cancer Clinical Trials in Connecticut

529 recruiting studies across 34 cities

All Trials in Connecticut

Phase
Trial Phase Location
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3Avon
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors—Avon
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialPhase 3Avon
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 3Avon
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerPhase 3Avon
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyPhase 2/3Avon
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaPhase 3Avon
A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth—Branford
Shield Post-Approval Study Protocol—Branford
Genomic Profiling in Cancer Patients—Bridgeport
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3Bridgeport
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerPhase 2Bridgeport
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing SurveillanceN/ABristol
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.Phase 2Danbury
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian CancerN/ADanbury
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseasePhase 3Danbury
Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseasePhase 2/3Danbury
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerPhase 3Danbury
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3Danbury
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial CancerPhase 3Danbury
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian CancerPhase 3Danbury
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic CancerPhase 3Danbury
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerPhase 3Danbury
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPhase 3Derby
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.Phase 3Derby
ATEMPT 2.0: Adjuvant T-DM1 vs THPhase 2Derby
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialPhase 2/3Derby
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisPhase 3Derby
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPhase 3Derby
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2/3Derby
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene MutationPhase 2Derby
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialPhase 2Derby
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentPhase 3Derby
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2Derby
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisPhase 3Derby
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers—Derby
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3Derby
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaPhase 3Derby
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase 2/3Derby
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasPhase 3Derby
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 3Derby
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer—Derby
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersPhase 2Derby
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/ADerby
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3Derby
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerPhase 3Derby
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal SarcomaPhase 3Derby
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerPhase 1/2Derby
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Phase 2Derby
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)Phase 2Derby
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaPhase 3Derby
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialPhase 3Derby
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple MyelomaPhase 1Derby
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal CavityPhase 2/3Derby
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 3Derby
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaPhase 2Derby
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsPhase 2Derby
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPhase 3Derby
The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyPhase 3Derby
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLCPhase 2Derby
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyPhase 2Derby
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral NeuropathyPhase 3Fairfield
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)Phase 3Farmington
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaPhase 3Farmington
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaPhase 3Farmington
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell CarcinomaPhase 3Farmington
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)Phase 2Farmington
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaPhase 3Farmington
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Phase 3Farmington
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Phase 3Farmington
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerPhase 3Farmington
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia GravisPhase 3Farmington
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)Phase 3Farmington
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Phase 3Farmington
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationPhase 3Farmington
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung CancerPhase 1/2Greenwich
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryPhase 2Greenwich
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous MelanomaN/AGuilford
Skin Color Matching in Head and Neck Reconstructive SurgeryN/AGuilford
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerPhase 3Guilford
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsPhase 1/2Hartford
A Dose Escalation Study of AV-380 in Cancer Patients With CachexiaPhase 1Hartford
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)Phase 3Hartford
A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat CancerPhase 3Hartford
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerPhase 3Hartford
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)Phase 2Hartford
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)Phase 2Hartford
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)Phase 3Hartford
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck CancerPhase 3Hartford
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerPhase 2Hartford
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPhase 3Hartford
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWTPhase 2Hartford
A Study of Lower Radiotherapy Dose to Treat Children With CNS GerminomaPhase 2Hartford
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)Phase 3Hartford
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)Phase 3Hartford
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing LossPhase 3Hartford
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerPhase 3Hartford
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerPhase 3Hartford
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCTPhase 2Hartford
A Study on the Effects of Exercise Therapy on Signs of Prostate CancerPhase 2Hartford
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal CancersPhase 2Hartford
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)Phase 2Hartford
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsPhase 3Hartford
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic CancerPhase 3Hartford
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerPhase 3Hartford
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix CancerN/AHartford
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsPhase 3Hartford
Beat Childhood Cancer Specimen Banking and Data Registry—Hartford
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaPhase 3Hartford
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier—Hartford
Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2N/AHartford
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed MedulloblastomaPhase 2Hartford
Digoxin Medulloblastoma StudyPhase 2Hartford
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaPhase 3Hartford
Easing Scan Anxiety in Pediatric Oncology Caregivers Through Meditation-based ProgramsN/AHartford
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasPhase 1/2Hartford
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast CancerN/AHartford
Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)—Hartford
Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens—Hartford
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube CancerPhase 3Hartford
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia—Hartford
Improving Communication Between AYA Oncology Patients and Clinicians: A Patient-Centered InterventionN/AHartford
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaPhase 3Hartford
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPhase 3Hartford
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of DiseasePhase 2Hartford
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies—Hartford
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate CancerPhase 4Hartford
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesPhase 1Hartford
Naxitamab Added to Induction for Newly Diagnosed High-Risk NeuroblastomaPhase 2Hartford
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease—Hartford
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted TherapyPhase 2/3Hartford
Pediatric Precision Laboratory Advanced Neuroblastoma TherapyPhase 2Hartford
Pembrolizumab, Olaparib, and Temozolomide for People With GliomaPhase 2Hartford
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerPhase 3Hartford
Project: Every Child for Younger Patients With Cancer—Hartford
Resource Intervention to Support Equity (RISE) in High-Risk NeuroblastomaN/AHartford
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—Hartford
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerN/AHartford
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsPhase 1/2Hartford
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPhase 3Hartford
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Phase 3Hartford
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsPhase 2Hartford
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerPhase 3Hartford
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma PatientsPhase 2Hartford
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NETPhase 3Hartford
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM TrialPhase 2Hartford
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Phase 3Hartford
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerPhase 3Hartford
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerPhase 2Hartford
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaPhase 2Hartford
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerPhase 1/2Hartford
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group StudyPhase 1/2Hartford
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaPhase 3Hartford
Tipifarnib and Naxitamab for Relapsed/Refractory NeuroblastomaPhase 2Hartford
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With CancerPhase 3Hartford
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPhase 1/2Hartford
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasPhase 2Hartford
Integrated Cancer Repository for Cancer Research—Manchester
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityPhase 3Middletown
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid TumorsPhase 1New Have
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCCPhase 2New Haven
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)Phase 3New Haven
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).Phase 1/2New Haven
A Clinical Study of YL205 in Patients With Advanced Solid TumorsPhase 1/2New Haven
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerPhase 3New Haven
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal CancerPhase 1/2New Haven
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate CancerPhase 1/2New Haven
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)Phase 3New Haven
A Clinical Trial to Assess COM503 in Participants With Advanced Solid MalignanciesPhase 1New Haven
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)Phase 1/2New Haven
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos StudyPhase 2New Haven
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal MetastasisN/ANew Haven
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid TumorsPhase 1New Haven
A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerPhase 1New Haven
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian CancerPhase 1New Haven
A First-in-Human Study of YL217 in Patients With Advanced Solid TumorsPhase 1New Haven
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid TumorsPhase 1/2New Haven
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)Phase 2/3New Haven
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)—New Haven
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus—New Haven
A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.Phase 1New Haven
A Phase 1 Study of IM-1021 in Participants With Advanced CancerPhase 1New Haven
A Phase 1 Study of IM-1617 in Participants With Advanced CancerPhase 1New Haven
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsPhase 1New Haven
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPhase 1New Haven
A Phase 1/2 Study to Investigate CRB-701 in Solid TumorsPhase 1/2New Haven
A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaPhase 2New Haven
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCLPhase 2New Haven
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPhase 3New Haven
A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerPhase 1/2New Haven
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic AlterationsPhase 2New Haven
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)Phase 3New Haven
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal CancerPhase 2New Haven
A Registry for People With T-cell Lymphoma—New Haven
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)Phase 3New Haven
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)Phase 1New Haven
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationPhase 1/2New Haven
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasPhase 1New Haven
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate CancerPhase 1New Haven
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid TumorsPhase 1New Haven
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)Phase 3New Haven
A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsPhase 1New Haven
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With EzabenlimabPhase 1New Haven
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.Phase 1New Haven
A Study of ASP1002 in Adults for Treatment of Solid TumorsPhase 1New Haven
A Study of ASP3082 in Adults With Advanced Solid TumorsPhase 1New Haven
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid TumorsPhase 1/2New Haven
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerPhase 2New Haven
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck CancerPhase 1/2New Haven
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerPhase 3New Haven
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 2New Haven
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerPhase 3New Haven
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid TumorsPhase 1New Haven
A Study of BG-C477 in Participants With Advanced Solid TumorsPhase 1New Haven
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 MutationsPhase 1/2New Haven
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AMLPhase 1New Haven
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid TumorsPhase 1New Haven
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasPhase 1/2New Haven
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)Phase 1New Haven
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePhase 3New Haven
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsPhase 3New Haven
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 2New Haven
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell CarcinomaPhase 3New Haven
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerPhase 3New Haven
A Study of GEN1106 in Participants With Solid TumorsPhase 1New Haven
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate CancerPhase 1/2New Haven
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)Phase 1New Haven
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesPhase 1/2New Haven
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell CarcinomaPhase 1New Haven
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsPhase 2New Haven
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyPhase 3New Haven
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast CancerPhase 1New Haven
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 MeningiomaPhase 2New Haven
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )Phase 1New Haven
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Phase 2New Haven
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesPhase 1New Haven
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisPhase 3New Haven
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid TumorsPhase 1/2New Haven
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)Phase 3New Haven
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesPhase 1/2New Haven
A Study of PHST001 in Advanced Solid TumorsPhase 1New Haven
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerPhase 1/2New Haven
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)Phase 1/2New Haven
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)Phase 1/2New Haven
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Phase 3New Haven
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerPhase 2/3New Haven
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical CancerPhase 2New Haven
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Phase 3New Haven
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Phase 3New Haven
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C MutationPhase 1/2New Haven
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsPhase 3New Haven
A Study of TAK-188 in Adults With Advanced or Spreading Solid TumorsPhase 1/2New Haven
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate CancerPhase 1/2New Haven
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractPhase 3New Haven
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid TumorsPhase 1New Haven
A Study of YL242 in Subjects With Advanced Solid TumorsPhase 1/2New Haven
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)Phase 3New Haven
A Study of ZL-1310 in Subjects With Small Cell Lung CancerPhase 1New Haven
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Phase 1New Haven
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With CancerPhase 1New Haven
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsPhase 1New Haven
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal CancerPhase 3New Haven
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab AdizutecanPhase 2New Haven
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)Phase 1/2New Haven
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Phase 2New Haven
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple MyelomaPhase 1New Haven
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid TumoursPhase 1/2New Haven
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)Phase 3New Haven
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple MyelomaPhase 1/2New Haven
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaPhase 3New Haven
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral EventsPhase 2New Haven
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid TumorsPhase 1New Haven
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerPhase 2New Haven
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)Phase 3New Haven
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerPhase 2New Haven
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)Phase 3New Haven
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)Phase 1New Haven
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)Phase 1/2New Haven
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid TumorsPhase 1/2New Haven
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid TumorsPhase 1/2New Haven
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)Phase 3New Haven
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)Phase 3New Haven
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)Phase 3New Haven
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)Phase 3New Haven
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid MalignanciesPhase 1New Haven
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid TumorsPhase 1New Haven
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLPhase 1New Haven
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsPhase 1New Haven
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)Phase 1New Haven
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.Phase 1New Haven
A Trial of Varenicline for E-cigarette CessationPhase 2New Haven
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder CancerPhase 3New Haven
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPhase 2/3New Haven
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate CancerPhase 1/2New Haven
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsPhase 1/2New Haven
AB821 in Adult Participants With Locally Advanced or Metastatic Solid TumorsPhase 1New Haven
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid TumoursPhase 1New Haven
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)Phase 1/2New Haven
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid TumorsPhase 1New Haven
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced CancersPhase 1New Haven
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsPhase 1New Haven
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid LeukemiaPhase 1New Haven
BBO-11818 in Adult Subjects With KRAS Mutant CancerPhase 1New Haven
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)Phase 1/2New Haven
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadPhase 1/2New Haven
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 AlterationsPhase 2New Haven
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic SyndromesPhase 2New Haven
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung CarcinomaPhase 2New Haven
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)Phase 1/2New Haven
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.Phase 2New Haven
CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCsPhase 2New Haven
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaPhase 3New Haven
Circulating Tumor DNAPhase 2New Haven
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid LeukemiaPhase 1/2New Haven
Collection and Storage of Tissue and Blood Samples From Patients With Cancer—New Haven
Colorectal Cancer Screening OutreachN/ANew Haven
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)Phase 2New Haven
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity CancerPhase 2/3New Haven
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior TreatmentPhase 2New Haven
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast TumorsN/ANew Haven
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions—New Haven
Congenital Uterine Anomalies: Identifying Cancer Associations and Genetic and Environmental Factors to Improve Clinical Care—New Haven
DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHYPhase 2New Haven
DALY II USA/ MB-CART2019.1 for DLBCLPhase 2New Haven
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid TumorsPhase 1New Haven
Drinking, Acetate, and StressN/ANew Haven
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 YearsPhase 4New Haven
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment—New Haven
Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck CancerPhase 2New Haven
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns—New Haven
Elranatamab in Patients With Relapsed or Refractory AL AmyloidosisPhase 1/2New Haven
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)Phase 2New Haven
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsPhase 1New Haven
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsPhase 1New Haven
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial CancerPhase 2New Haven
Evaluation of a Mobile App Program for Coping With CancerN/ANew Haven
Evaluation of the Q-Pad hrHPV Test System for Identifying PrecancerN/ANew Haven
Evolutionary Clinical Trial for Novel Biomarker-Driven TherapiesPhase 2New Haven
Exercise in Metastatic Breast Cancer: EMBodyN/ANew Haven
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid TumorsPhase 1New Haven
FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine TherapyPhase 2New Haven
FOG-001 in Locally Advanced or Metastatic Solid TumorsPhase 1/2New Haven
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid TumorsPhase 1New Haven
Fabry Disease Registry & Pregnancy Sub-registry—New Haven
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCPhase 1/2New Haven
First in Human Study of TUB-030 in Patients With Advanced Solid TumorsPhase 1/2New Haven
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid TumorsPhase 1New Haven
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerPhase 1New Haven
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsPhase 1/2New Haven
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous PolypsN/ANew Haven
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast CancerN/ANew Haven
Hyperfractionated Dual Equivalent Fractionated Radiation TherapyN/ANew Haven
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPhase 2New Haven
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid MalignanciesPhase 1New Haven
Iadademstat + SBRT With Atezo in ES-SCLCPhase 1New Haven
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine TherapyPhase 2New Haven
International Registry for Men With Advanced Prostate Cancer (IRONMAN)—New Haven
Investigation of Lymph Node Biology in Kidney CancerN/ANew Haven
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment RegimensPhase 3New Haven
Language Network Prehab Via fMRI NeurofeedbackN/ANew Haven
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU—New Haven
Life at 100.4: An Immersive Social Virtual Reality (VR) Education Tool for Adolescent and Young Adult Cancer Patients and CaregiversN/ANew Haven
Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBCN/ANew Haven
Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer SurvivorsN/ANew Haven
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T CellsPhase 2/3New Haven
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Phase 3New Haven
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer—New Haven
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid TumorsPhase 1New Haven
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)Phase 2New Haven
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone LymphomaPhase 2New Haven
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerPhase 2New Haven
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)Phase 3New Haven
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid TumorsPhase 1/2New Haven
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell CarcinomaPhase 1New Haven
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerPhase 1New Haven
Optimizing Surgical Decisions in Young Adults With Breast CancerN/ANew Haven
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerPhase 3New Haven
Pan Tumor Rollover StudyPhase 2New Haven
Pancreatic Cancer Early Detection Consortium—New Haven
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaPhase 2New Haven
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)Phase 2New Haven
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.Phase 1New Haven
Phase 1 Study of PF-08046033 in Advanced Solid TumorsPhase 1New Haven
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsPhase 1/2New Haven
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerPhase 1/2New Haven
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesPhase 1/2New Haven
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067Phase 1/2New Haven
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected TumorsPhase 1New Haven
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaPhase 3New Haven
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerPhase 3New Haven
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationPhase 3New Haven
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsPhase 3New Haven
Phase 3 Trial of eRapa in Patients With Familial Adenomatous PolyposisPhase 3New Haven
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable TumorsPhase 2New Haven
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaPhase 3New Haven
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerPhase 3New Haven
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal ResectionsN/ANew Haven
Pre-Operative Window of ET to Inform RT Decisions (POWER II)Phase 3New Haven
Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System—New Haven
QTX3034 in Patients With KRAS G12D MutationPhase 1New Haven
Rash & Diarrhea Prophylaxis With CapivasertibPhase 2New Haven
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring—New Haven
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)—New Haven
Revumenib in Combination With 7+3 + Midostaurin in AMLPhase 1New Haven
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)Phase 3New Haven
SNV1521 in Participants With Advanced Solid TumorsPhase 1New Haven
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaPhase 3New Haven
Saci Nivo Rela for TNBCPhase 1/2New Haven
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive DiseasePhase 2New Haven
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPhase 1New Haven
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCPhase 2New Haven
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2Phase 3New Haven
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaPhase 3New Haven
Statins to Prevent Cancer Associated Blood ClotsPhase 4New Haven
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic TumorsPhase 1New Haven
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerPhase 1New Haven
Study of AVZO-021 in Patients With Advanced Solid TumorsPhase 1/2New Haven
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTPhase 3New Haven
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaPhase 3New Haven
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Phase 3New Haven
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate CancerPhase 1/2New Haven
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerPhase 1New Haven
Study of INCA036978 in Participants With Myeloproliferative NeoplasmsPhase 1New Haven
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid TumorsPhase 1/2New Haven
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)Phase 1New Haven
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid TumorsPhase 1New Haven
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaPhase 2New Haven
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic CancerPhase 2/3New Haven
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationPhase 1/2New Haven
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)Phase 3New Haven
Study of PF-07248144 in Advanced or Metastatic Solid TumorsPhase 2New Haven
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerPhase 3New Haven
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsPhase 1/2New Haven
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsPhase 1New Haven
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsPhase 1New Haven
Study of SGR-3515 In Participants With Advanced Solid Tumors.Phase 1New Haven
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other CancersPhase 1/2New Haven
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIPhase 2New Haven
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerPhase 3New Haven
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaPhase 1New Haven
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsPhase 1New Haven
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )Phase 3New Haven
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.Phase 3New Haven
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced MalignanciesPhase 1New Haven
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisPhase 3New Haven
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant TherapyPhase 1New Haven
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsPhase 1/2New Haven
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)Phase 1/2New Haven
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)Phase 3New Haven
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdPhase 2New Haven
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their CaregiversN/ANew Haven
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid TumorsPhase 1/2New Haven
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain CancerPhase 3New Haven
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)Phase 2New Haven
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaPhase 2New Haven
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialPhase 2New Haven
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPhase 1New Haven
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell CarcinomaPhase 2New Haven
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or AstrocytomaPhase 1New Haven
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromesPhase 1New Haven
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaPhase 1New Haven
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and EffectivenessPhase 1/2New Haven
The Cancer of the Pancreas Screening-5 CAPS5)StudyPhase 3New Haven
The DRAGON 2 TrialN/ANew Haven
The Dragon PLC Trial (DRAGON-PLC)N/ANew Haven
The EXPLORE MG Registry for Myasthenia Gravis—New Haven
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALLPhase 2New Haven
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Phase 1/2New Haven
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated LymphedemaN/ANew Haven
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)—New Haven
The SUGAR Study; SBRT and Relugolix) for Prostate CancerPhase 2New Haven
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid TumorsPhase 1New Haven
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune SystemPhase 2New Haven
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) LevelsPhase 2New Haven
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell CarcinomaPhase 2New Haven
Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial CancerN/ANew Haven
Trial of Trastuzumab Deruxtecan in Previously Treated HER2Phase 2New Haven
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid TumorsPhase 1New Haven
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid TumorsPhase 1New Haven
Unified Network for Integrated Fluid Collection at Yale—New Haven
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)Phase 2New Haven
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)Phase 3New Haven
XTX301 in Patients With Advanced Solid TumorsPhase 1/2New Haven
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell CarcinomaPhase 3Newhaven
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their BodyPhase 1/2North Haven
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid TumorsPhase 1North Haven
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerPhase 2North Haven
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)Phase 3North Haven
A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals—Norwalk
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaPhase 1Norwalk
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsPhase 2Norwalk
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast CancerPhase 1Norwalk
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast CancerPhase 2Norwalk
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationPhase 3Norwalk
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer—Norwalk
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.—Norwich
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyPhase 3Norwich
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyPhase 3Norwich
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Phase 3Norwich
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)Phase 2Norwich
GEMINI-NSCLC: NSCLC Biomarker Study—Norwich
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Phase 2/3Norwich
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositivePhase 2/3Norwich
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsPhase 1/2Norwich
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology—Norwich
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorPhase 3Norwich
Visugromab in Cachexia International TrialPhase 2/3Norwich
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCPhase 3Stamford
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy—Stamford
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)Phase 3Stamford
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)Phase 3Stamford
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialPhase 3Stamford
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening—Stamford
E-Mindfulness Approaches for Living After Breast CancerPhase 3Stamford
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCPhase 2Stamford
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLPhase 2Stamford
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS MutationsPhase 3Stamford
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal CancerPhase 3Stamford
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialPhase 2Stamford
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialPhase 3Stamford
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles—Waterbury
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)Phase 3West Haven
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—West Haven
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects—West Haven
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponsePhase 3West Haven
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate CancersPhase 2West Haven
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRIN/AWest Haven
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer SurveillancePhase 2West Haven
Repositioning Immunotherapy in VetArans With Lung CancerPhase 2West Haven

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.